Neuronetics (STIM) priced an underwritten public offering of 18.8 million common shares at $1.60 each for expected gross proceeds of about $30 million, representing a 20% discount from the stock's last closing price, the company said late Tuesday.
The underwriters were granted a 30-day option to purchase up to an additional 2.8 million shares.
Net proceeds will be used for debt repayments and for general corporate purposes, the company said.
Closing is expected to occur on or about Thursday, subject to customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.